Coming Off a GLP-1 Without Regaining the Fat

Most people who lose weight on a GLP-1 medication regain a large share of it once they stop. The STEP 1 trial extension put a number on it: participants who came off semaglutide regained a mean of 11.6 percentage points of body weight in the year after stopping, roughly two-thirds of everything they had lost. The reason the loss does not hold is rarely willpower. It is that a meaningful portion of the weight lost on a GLP-1 is muscle, and muscle is what protects your resting metabolic rate. If you spend your months on the drug building and keeping muscle through strength training and adequate protein, the exit strategy is already in place. The strength base you build is the thing that makes the fat loss stick after the medication stops.

TL;DR

Why weight comes back after a GLP-1

GLP-1 medications work, in large part, by reducing appetite. They slow gastric emptying and signal fullness, so you eat less without the constant hunger that derails most diets. While the drug is in your system, a calorie deficit is easier to hold than it has ever been. That is the mechanism, and it is genuinely powerful.

The problem is what happens when the signal stops. In the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, participants lost a mean of 17.3% of body weight over 68 weeks on semaglutide plus lifestyle support. Then the drug was withdrawn. One year later, they had regained a mean of 11.6 percentage points, leaving a net loss of only 5.6%. Two-thirds of the result was gone. The appetite returns, the deficit closes, and the weight follows.

This is not a moral failure on the part of the patient, and it is not a reason to dismiss the medication. It is a structural feature of how appetite-suppressing drugs work: take away the suppression, and the body returns to the behaviour the drug was overriding. A GLP-1 is a tool that buys you a window. What you build inside that window decides whether the window closing matters.

The muscle you lose is the hidden cost

When you lose weight quickly, not all of the loss is fat. Some of it is lean mass, which is mostly skeletal muscle. This is true of any rapid weight loss, but it is a specific concern with GLP-1 medications because the appetite suppression is so effective that protein intake and training often fall away alongside the calories.

A 2024 review in Diabetes, Obesity and Metabolism by Neeland and colleagues examined exactly this, the loss of lean body mass on GLP-1-based therapies and how to mitigate it. The share of weight lost as lean mass varies across studies, but it is consistently large enough to matter, and it runs higher in older, frailer, or already sarcopenic patients, the group Catalyst works with most. The conclusion is the centre of this whole story: without countermeasures, some lean mass loss is hard to avoid, and the countermeasure with the strongest exercise-science support, as the next section shows, is resistance training with adequate protein alongside it.

This matters because the scale does not tell you what kind of weight you lost. A patient who drops 15 kg can look like a clear success while having shed several kilograms of muscle. That muscle does not announce itself. It shows up later, as a slower metabolism, a weaker grip, and a body that regains fat more readily than it did before.

How muscle defends your resting metabolic rate

Your resting metabolic rate is the energy your body burns at rest, and it accounts for the majority of your daily calorie expenditure. Skeletal muscle is one of the more metabolically active tissues you carry. When you lose muscle, your resting metabolic rate falls, which means you burn fewer calories at rest than you did before, even at the same body weight.

Now connect that to regain. You come off the GLP-1, your appetite returns to baseline, but your metabolism is running lower than it was before you started, because you lost muscle along the way. You are eating like your old self with the engine of a smaller person. That gap is a tailwind for fat regain. It is part of why the weight does not just creep back to where it started, but often does so faster than the patient expects.

The 2025 meta-analysis by Binmahfoz and colleagues in BMJ Open Sport & Exercise Medicine is the cleanest evidence on the fix. Across trials of dietary weight loss, adding resistance exercise protected against the loss of fat-free mass (standardised mean difference 0.40, p=0.0003), increased the amount of fat lost (SMD -0.36, p<0.00001), and produced large gains in muscle strength (SMD 2.36). In plain terms: train with resistance while you lose weight, and you keep more muscle, lose more fat, and get stronger. The preserved muscle is what holds your resting metabolic rate up.

Why the strength base is the exit strategy

Most conversations about coming off a GLP-1 focus on the taper: how slowly to reduce the dose, what to expect from returning appetite. Those are real clinical questions for your prescriber. But the taper is not the exit strategy. The exit strategy is the muscle you carried through the months on the drug.

Think of it as two bodies arriving at the same finish line. The first lost 15 kg on the medication with no training and low protein, shedding several kilograms of muscle. The second lost the same 15 kg while training twice a week and eating enough protein, and kept nearly all of their muscle. On the day the drug stops, the first has a depressed metabolism and a weak foundation, and regain is the path of least resistance. The second has a defended metabolic rate and a strength base that supports an active life without the medication. Same weight lost, completely different durability.

This is the same principle behind body recomposition after 40, and it is why I keep returning to it. The goal was never the number on the scale. It is the body composition underneath it. A GLP-1 can move the number fast. Only training and protein move the composition in the direction that lasts. If you have read my earlier pieces on GLP-1 muscle loss and why you still need a trainer on Ozempic, this is the same argument carried to its conclusion: the work you do on the drug is what determines what you keep off it.

What to do while you are still on the drug

The window to build your exit strategy is while the medication is working, not after it stops. Two things carry most of the weight, and neither is complicated.

The first is resistance training, two to three sessions per week, built around compound movements that load multiple muscle groups: squats, hinges, presses, pulls, and loaded carries. The load should be meaningful, heavy enough to be genuinely challenging in the working range. This is the stimulus that tells your body to keep the muscle it would otherwise surrender during a rapid deficit. Conditioning and walking have their place for cardiovascular health, but they do not protect muscle. Resistance training does.

The second is protein. Aim for at least 1.2 g per kg of body weight per day, distributed across three to four meals. This is the harder of the two on a GLP-1, precisely because the drug suppresses appetite so well. When you are not hungry, hitting a protein target takes deliberate planning: a protein-forward breakfast, a substantial lunch, and a shake to fill the gap if a meal falls short. Adequate protein gives the training something to build with. Without it, you are sending the signal to keep muscle without supplying the raw material.

Whether to start, continue, or stop a GLP-1 is a medical decision that belongs with your GP or specialist, made on your full clinical picture. I am not in that conversation, and this article is not advice to begin or end a prescription. What I can tell you is that the training and protein side of the equation is what determines how much of the result survives the day the medication stops, and that side is entirely in your control.

The Singapore context, and where Catalyst fits

GLP-1 medications are increasingly part of the weight-management picture for Singapore executives, often prescribed through the same clinics and specialist consultations that handle their annual health screening. The medication is doing more of the appetite work than any diet ever could. What it does not do, on its own, is protect the muscle and the metabolic rate that decide whether the loss holds.

That is the gap we are built to fill. At Catalyst Performance, our private personal training studio at Manulife Tower above Telok Ayer (DT18), we treat the months on a GLP-1 as a build window, not a passive weight-loss phase. The work is to keep as much muscle as possible while the fat comes off, so that the body composition at the end is durable rather than fragile.

Every member starts with the 4-Pillar Healthspan Assessment, our 60-minute in-studio evaluation across body composition, cardiorespiratory fitness, stability, and strength. For someone on or considering a GLP-1, the body composition and strength pillars are the ones that matter most: they establish a baseline of lean mass and grip strength, so we can track whether the weight you are losing is fat or muscle, and adjust the programme before muscle loss becomes a problem. Our strength on GLP-1 track is built specifically for this, around the principle that the exit strategy is the strength base. The medication can move the number. The training is what makes the loss stick.

Frequently asked questions

Q. Will I regain the weight after I stop a GLP-1?

Many people do. The STEP 1 trial extension found participants regained about two-thirds of their lost weight within a year of stopping semaglutide. Regain happens because appetite returns and, often, because muscle lost during the rapid weight loss has lowered the resting metabolic rate. Keeping muscle through resistance training and adequate protein while on the drug is the most direct way to make the loss more durable.

Q. How much of GLP-1 weight loss is muscle?

Studies vary, but a substantial share of the weight lost on GLP-1-based therapy, often a quarter or more, is lean (muscle) mass rather than fat, and the proportion runs higher in older, frailer, or already sarcopenic people. Resistance training and adequate protein intake are the evidence-based strategies to protect muscle and shift more of the loss toward fat.

Q. Does strength training really protect against weight regain?

Indirectly, yes. A 2025 BMJ meta-analysis found that resistance exercise during weight loss preserves fat-free mass, increases fat loss, and builds strength. Preserving muscle helps defend your resting metabolic rate, which is one of the mechanisms behind regain. Training does not override returning appetite, but it removes the metabolic tailwind that makes regain easier after the drug stops.

Q. How much protein should I eat on a GLP-1?

At least 1.2 g per kg of body weight per day, spread across three to four meals, is a reasonable target for protecting muscle during weight loss. This is harder on a GLP-1 because appetite is suppressed, so it usually takes deliberate planning rather than eating to hunger. Confirm any specific target with your doctor or dietitian if you have kidney concerns or other medical conditions.

Q. Should I stop my GLP-1 if I am worried about muscle loss?

That is a question for your GP or specialist, not something to decide on your own. Starting, continuing, and stopping a GLP-1 is a clinical decision based on your full medical picture. What is in your control regardless of the medication is the training and protein that protect your muscle and metabolic rate, which is the side of the equation that determines how much of the result lasts.

Citations

Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. pmc.ncbi.nlm.nih.gov

Binmahfoz A, Dighriri A, Gray C, Gray SR. (2025). Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: a systematic review and meta-analysis. BMJ Open Sport & Exercise Medicine, 11(3), e002363. pmc.ncbi.nlm.nih.gov

Neeland IJ, Linge J, Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(Suppl 4), 16-27. pubmed.ncbi.nlm.nih.gov